Fatty liver disease (MASLD/MASH) trials in France

In France 32 Also abroad 367

32 trials · From ClinicalTrials.gov and EU CTIS (euclinicaltrials.eu), checked 11 November 2026. Ask the study team whether a trial fits you.

No phaseNot yet taking people in France
Immunological Signatures of MASLD and MASH in Patients With Type 1 Diabetes
Where
Paris
Age
18 years and over
People
1,000
Run by
Assistance Publique - Hôpitaux de Paris
See details and how to joinNCT07927647
Phase 3Taking people
A Study Evaluating Efruxifermin in Subjects With Non-Cirrhotic Nonalcoholic Steatohepatitis (NASH)/Metabolic Dysfunction-Associated Steatohepatitis (MASH) and Fibrosis
Where
Angers, Clichy, Créteil, Limoges, Lyon, Marseille, Montpellier Cedex 5, Nice, Paris, Strasbourg, Toulouse, Vandœuvre-lès-Nancy, Versailles
Age
18 years to 80 years
People
1,650 worldwide
Run by
Akero Therapeutics, Inc
See details and how to joinNCT06215716
Phase 3Taking people
LIVERAGE™: A Study to Test Whether Survodutide Helps People With a Liver Disease Called NASH/MASH Who Have Moderate or Advanced Liver Fibrosis
Where
Amiens Cedex 1, Angers, Clichy, Creteil, Dijon, Le Chesnay Rocquencourt, Lille, Lyon Cedex 04, Nice, Paris, Pessac, Pierre-Bénite, Toulouse Cedex 9
Age
18 years and over
People
1,800 worldwide
Run by
Boehringer Ingelheim
See details and how to joinNCT06632444 · EU 2024-513739-25-00
Phase 3Taking people
LIVERAGE™ - Cirrhosis: A Study to Test Whether Survodutide Helps People With a Liver Disease Called NASH/MASH Who Have Cirrhosis
Where
Amiens Cedex 1, Angers, Clichy, Dijon, Le Chesnay Rocquencourt, Lille Cedex, Lyon Cedex 04, Nice, Paris, Toulouse Cedex 9, Assistance Publique-Hopitaux de Paris (AP-HP) - Hopitaux Universitaires Henri Mondor (Hopital Henri-, CHU Bordeaux Hopital Haut-Lévêque, HCL - Hopital Lyon Sud - Endocrinologie Diabetologie Nutrition
Age
18 years and over
People
1,590 worldwide
Run by
Boehringer Ingelheim
See details and how to joinNCT06632457 · EU 2024-513741-36-00
Phase 3Taking people
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Safety and Efficacy of Efruxifermin in Subjects with Compensated Cirrhosis Due to Nonalcoholic Steatohepatitis (NASH)/Metabolic Dysfunction-Associated Steatohepatitis (MASH)
Where
Angers, Clichy, Creteil, Le Chesnay Rocquencourt, Lille, Limoges Cedex 1, Lyon Cedex 04, Marseille, Montpellier Cedex 5, Nice, Paris, Pessac, Strasbourg Cedex, Toulouse Cedex 9, Vandoeuvre Les Nancy, Vénissieux
Age
18 years and over
People
205 worldwide
Run by
Akero Therapeutics Inc.
See details and how to join2024-512895-36-00 · EU 2024-512895-36-00
Phase 3Taking people
A Study Evaluating the Efficacy and Safety of Pegozafermin in Participants With MASH and Fibrosis (ENLIGHTEN-Fibrosis)
Where
Amiens Cedex 1, Angers, Clichy, Lille Cedex, Limoges Cedex 1, Lyon Cedex 04, Montpellier Cedex 5, Nantes, Nice, Paris, Paris Cedex 13, Pessac, Pierre-Bénite, Strasbourg Cedex, Toulouse Cedex 3, Toulouse Cedex 9, Vandoeuvre Les Nancy, Vénissieux, Villejuif
Age
18 years to 80 years
People
1,350 worldwide
Run by
Hoffmann-La Roche
See details and how to joinNCT06318169 · EU 2023-509912-27-00
Phase 3Taking people
A Study to Evaluate the Efficacy and Safety of Pegozafermin in Participants With Compensated Cirrhosis Due to MASH
Where
Amiens Cedex 1, Clichy, Dijon, Limoges Cedex 1, Lyon Cedex 04, Montpellier Cedex 5, Nice, Paris, Pessac, Strasbourg Cedex, Toulouse Cedex 3, Toulouse Cedex 9, Vandoeuvre Les Nancy, Vénissieux, Villejuif
Age
18 years to 75 years
People
1,800 worldwide
Run by
Hoffmann-La Roche
See details and how to joinNCT06419374 · EU 2023-510395-31-00
No phaseTaking people
"Constitution of a Biological Collection to Establish Preclinical Translational Models for the Study of Tumors and Chronic Liver Diseases".
Where
Strasbourg
Age
18 years and over
People
800
Run by
Institut National de la Santé Et de la Recherche Médicale, France
See details and how to joinNCT04690972
Phase 3Not yet taking people in France
A pivotal clinical study to investigate the safety and efficacy of efimosfermin compared with placebo in adult participants with compensated cirrhosis due to Metabolic dysfunction-associated steatohepatitis (MASH)
Where
Amiens Cedex 1, Angers, Bobigny, Clichy, Creteil, Lille Cedex, Lyon Cedex 04, Nice, Paris, Pessac, St Herblain, Strasbourg Cedex, Vandoeuvre Les Nancy, Villejuif
Age
18 years and over
People
382 worldwide
Run by
Glaxosmithkline Research & Development Limited
See details and how to join2026-525755-82-00 · EU 2026-525755-82-00
Phase 3Not yet taking people in France
A study to investigate safety and efficacy of efimosfermin compared with placebo in adult participants with compensated cirrhosis (stage F4 fibrosis) due to MASH (NEBULA-2)
Where
Amiens Cedex 1, Angers, Bobigny Cedex, Clichy, Creteil Cedex, Lille, Lyon Cedex 04, Nice, Paris, Paris Cedex 13, Pessac, St Herblain, Strasbourg Cedex, Vandoeuvre Les Nancy, Villejuif
Age
18 years and over
People
69 worldwide
Run by
Glaxosmithkline Research & Development Limited
See details and how to join2026-525757-37-00 · EU 2026-525757-37-00
Phase 3Taking people
A Study Evaluating Efruxifermin in Subjects With Compensated Cirrhosis Due to NASH/MASH
Where
Angers, Clichy, Créteil, Le Chesnay, Lille, Limoges, Lyon, Marseille, Montpellier Cedex 5, Nice, Paris, Pessac, Strasbourg, Toulouse, Vandœuvre-lès-Nancy
Age
18 years to 80 years
People
2,150 worldwide
Run by
Akero Therapeutics, Inc
See details and how to joinNCT06528314
Phase 3Taking people
A Master Protocol of Multiple Agents in Adults With Metabolic Dysfunction-Associated Steatotic Liver Disease (SYNERGY-Outcomes)
Where
Amiens, Angers, Besançon, Clichy, Dijon, La Roche-sur-Yon, Lille, Limoges, Nice, Paris, Pessac, Pierre-Bénite, Rennes, Strasbourg, Toulouse
Age
18 years and over
People
4,500 worldwide
Run by
Eli Lilly and Company
See details and how to joinNCT07165028 · EU 2025-522674-36-00
Phase 3Taking people
A Clinical Study to Investigate the Safety and Tolerability of Efimosfermin Alfa Injection in Participants With Known or Suspected F2- or F3-stage MASH
Where
Amiens Cedex 1, Angers, Besançon, Bobigny, Clermont-Ferrand, Clichy, Creteil Cedex, Lille Cedex, Lyon Cedex 04, Nice, Paris, Paris Cedex 12, Pessac, Pierre-Bénite, Rennes, St Herblain, Strasbourg Cedex, Vandoeuvre Les Nancy, Villejuif Cedex
Age
18 years to 75 years
People
1,250 worldwide
Run by
GlaxoSmithKline
See details and how to joinNCT07221188 · EU 2025-523674-16-00
No phaseTaking people
NAC- NAFLD And Cushing
Where
Angers, Bordeaux, Brest, Grenoble, Lille, Nantes, Vandœuvre-lès-Nancy
Age
18 years and over
People
100
Run by
University Hospital, Angers
See details and how to joinNCT05881005
No phaseTaking people
Screening in Primary Care of Advanced Liver Fibrosis in NAFLD and/or Alcoholic Patients
Where
Angers, Baugé-en-Anjou, Bécon-les-Granits, Chalonnes-sur-Loire, Combourg, Liffré, Montreuil-Bellay, Rennes, Segré, Val-couesnon
Age
40 years to 80 years
People
1,788
Run by
University Hospital, Angers
See details and how to joinNCT05699018
No phaseTaking people
Efficacy of 12-week Daytime Restricted Eating on Hepatic Steatosis of Obesity
Where
Angers, Bordeaux, Dijon, Lyon, Marseille, Montpellier, Nantes, Paris, Rennes
Age
18 years to 65 years
People
72
Run by
Nantes University Hospital
See details and how to joinNCT07378072
No phaseTaking people
Assessment of Gut Microbiota-Derived Amino Acid Metabolite Production in Patients With MASLD
Where
Pierre-Bénite
Age
18 years to 80 years
People
24
Run by
Hospices Civils de Lyon
See details and how to joinNCT07313007
No phaseTaking people
Exploratory Study of MRI Biomarkers of NASH
Where
Angers, Rennes
Age
18 years and over
People
110
Run by
University Hospital, Angers
See details and how to joinNCT06626074
No phaseTaking people
A Randomized Controlled Study Evaluating Bariatric Surgery as a Treatment for Severe NASH With Advanced Liver Fibrosis in Non-severe Obese Patients
Where
Lille
Age
18 years to 65 years
People
100
Run by
University Hospital, Lille
See details and how to joinNCT03472157
No phaseTaking people
CHronic Hepatopathies Associated With ALcohol Consumption aNd metAbolic Syndrome
Where
Nice
Age
18 years and over
People
710
Run by
Institut National de la Santé Et de la Recherche Médicale, France
See details and how to joinNCT05623150
No phaseNot yet taking people in France
Screening for MASLD-related Advanced Fibrosis in Type 2 Diabetes
Where
Caluire-et-Cuire, Lyon, Saint-Maurice-l'Exil, Sathonay-Camp
Age
18 years and over
People
1,714
Run by
Hospices Civils de Lyon
See details and how to joinNCT07270822
No phaseNot yet taking people in France
Impact of Artificial Intelligence Algorithm-driven Versus Standard Lifestyle Intervention in Non-Alcoholic Fatty Liver Disease - A Multicenter, Randomized, Open-label, Controlled Trial
Where
Angers, Clichy, Dijon, Lyon, Nantes, Paris, Pessac, Toulouse
Age
18 years and over
People
216
Run by
University Hospital, Toulouse
See details and how to joinNCT07497750
No phaseTaking people
Type 2 DIAbeTes With NAFLD: innOvative Biomarkers of Disease progressioN and clInical outComes
Where
Dijon, Lyon, Nantes, Pierre-Bénite
Age
40 years to 80 years
People
500
Run by
Hospices Civils de Lyon
See details and how to joinNCT06567990
Phase 3Taking people
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Safety and Efficacy of Efruxifermin in Subjects with Non-Cirrhotic Nonalcoholic Steatohepatitis (NASH)/Metabolic Dysfunction-Associated Steatohepatitis (MASH) and Fibrosis
Where
Angers, Clichy, Creteil, Le Chesnay Rocquencourt, Limoges Cedex 1, Lyon Cedex 04, Marseille, Montpellier Cedex 5, Nice, Paris Cedex 13, Strasbourg Cedex, Toulouse Cedex 9, Vandoeuvre Les Nancy
Age
18 years and over
People
244 worldwide
Run by
Akero Therapeutics Inc.
See details and how to join2023-505141-48-00 · EU 2023-505141-48-00
No phaseTaking people
Study of the Link Between MASH ( Metabolic Dysfunction-Associated Steatohepatitis) and MAMs (Mitochondria-Associated Membranes ) Alteration in Patients Undergoing Bariatric Surgery - MAMBA
Where
Lyon, Pierre-Bénite
Age
18 years to 99 years
People
20
Run by
Hospices Civils de Lyon
See details and how to joinNCT06868992